eXTReMe Tracker
Gene Therapy Net RSS feed Follow Gene Therapy Net on Twitter LinkedIn - Gene Therapy Net discussion group Facebook - Gene Therapy Net

ChinaBio® Today

ChinaBio® Today provides daily news, commentary and analysis on public and private China biotech companies and industry events, as well as global issues affecting the China market.

Related Links

Review of Gene Therapy development in China

For the first time, a gene therapy-based treatment has been given the go-ahead by regulatory authorities. In 2001, the 500th gene therapy clinical trial was submitted to the FDA/NIH for approval. Whereas in 2003, the first commercial gene therapy medicine (Gendicine) was available on the market in China.

China's medicines authority (China State Food & Drug Administration, SDFA) approved the cancer therapy after it achieved promising results in a clinical trial on October 16, 2003. The treatment, called Gendicine, has been launched commercially by SiBiono GeneTech Co. of Shenzhen, Guangdong province. Gendicine was approved for the treatment of head and neck squamous cell carcinoma. The gene therapy product is an adenovirus vector carrying the p53 tumour-suppressor gene. Gendicine is similar to Advexin developed by the Texas-based Introgen Therapeutics. Advexin is still waiting for FDA approval.

The results of the Gendicine clinical trial are published in Human Gene Therapy, says Zhaohui Peng, the SiBiono company's founder and head. Gendicine's approval was announced earlier but has gone largely unnoticed outside China (see also China approves first gene therapy. There were concerns about the approval among researchers elsewhere in the world as to quality of the trials performed and thereby the safety and efficacy of the treatment (Controversial Chinese gene-therapy drug entering unfamiliar territory). The available clinical data and conclusions drawn were obtained from a relatively small number of patients in clinical trials. There have been more patients treated, but the clinical data of these patients are hard to access, partly due to the fact that they were published only in Chinese journals. Furthermore, it seemed that approval had been made on the basis of tumour shrinkage rather than extension of patient lifetime (An update on gene therapy in China). Despite these concerns, patients have flown to China to undergo therapy (see Medical Tourism)

Shanghai Sunway Biotech Co. Ltd. announced in November 2005 that the SFDA has approved Oncorine (H101), an oncolytic adenovirus, to be used in combination with chemotherapy as a treatment for patients with late stage refractory nasopharyngeal cancer. This marks the first oncolytic viral therapy approved by any regulatory agency in the world and this is the second commercial gene therapy product. H101 is essentially a modified version of Onyx-015, initially developed by Onyx Pharmaceuticals. Besides Oncorine, Shanghai Sunway Biotech develops a tumor-targeted recombinant adenovirus injection (H102) and an oncolytic recombinant adenovirus injection (H103) for treatment of cancer. H102 specifically targets primary hepatocellular carcinoma. H103 adenoviruses lyses the tumor cells and expresses Hsp70 that can potently stimulate an antitumor immune response.

See the following reviews regarding the developments of gene therapy in China:

 


Exchange Grants

List of funding organisations involved in promoting research co-operation with China.

CO-REACH Co-ordination of research between Europe and China
Science and Technology Fellowship programme in China

Chinese Literature

Chinese Journal of Cancer
Chinese Medicine
Journal of Chinese Clinical Medicine

China National Knowledge Infrastructure (CNKI) is a key national project of China. CNKI now serves more than four hundred universities, public libraries, research institutions, enterprises, and hospitals in more than twenty countries.

Wanfang Database is an affiliate of Chinese Ministry of Science & Technology and has been the leading information provider in China since 1950s. With a wide range of database resources and value-added services, Wanfang Data has become a gateway to understand Chinese culture, medicine, business, science, etc.

The Chinese East Asian Gateway Service will deliver Chinese academic articles to individual researchers or non-profit institutions / organizations. This service focuses on Chinese academic publications in Chinese libraries not held by or available from libraries in the United States.

Chongqing VIP Information Co., Ltd. Its online Chinese databases have collected Chinese newspapers, Chinese journals and foreign journals. It is a Chinese Scientific Journals Fulltext Database, which is the biggest national comprehensive documentary database.

Advertise on this site?